Prediction of therapeutic doses of beta-adrenergic receptor blocking agents based on quantitative structure-pharmacokinetic/pharmacodynamic relationship.

No abstract is available for this paper.

• Publication year

  1993

• Venue

  Biological and Pharmaceutical Bulletin

• Publication date

  1993-12-15

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1248/BPB.16.1251PMID 7907513
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Receptor binding of propranolol is the missing link between plasma concentration kinetics and the effect-time course in man

  2004cited by this paper
• Beta-adrenergic blockers.

  2003cited by this paper
• A MODIFICATION OF RECEPTOR THEORY

  1997cited by this paper
• Spare Receptors for β‐Adrenoceptor-Mediated Positive Inotropic Effects of Catecholamines in the Human Heart

  1992cited by this paper
• Effect of beta-adrenoceptor blockade on exercise-induced plasma catecholamine concentrations and their dissipation profile.

  1987cited by this paper
• Characterization of beta-1 and beta-2 adrenoceptors in guinea pig atrium: functional and receptor binding studies.

  1987cited by this paper
• Propranolol pharmacodynamic modeling using unbound and total concentrations in healthy volunteers

  1987cited by this paper
• Beta 2 receptors on myocardial cells in human ventricular myocardium.

  1986cited by this paper
• Regional distribution of beta-adrenoceptors in the human heart: coexistence of functional beta 1- and beta 2-adrenoceptors in both atria and ventricles in severe congestive cardiomyopathy.

  1986cited by this paper
• Receptor binding characteristics and pharmacokinetic properties as a tool for the prediction of clinical effects of beta-blockers.

  1985cited by this paper
• Effect of altered plasma protein binding on pharmacokinetics and pharmacodynamics of propranolol in rats after surgery: role of alpha-1-acid glycoprotein.

  1985cited by this paper
• Quantitative relationships between structure and pharmacokinetics of beta-adrenoceptor blocking agents in man

  1984cited by this paper
• Beta-receptor blocking potencies of the three newly synthesized beta-adrenergic antagonists (S-596, K-351, N-696) as assessed with the radioligand binding assay method in rat cardiac muscle membrane treated with neuraminidase.

  1984cited by this paper
• Multifactorial actions of beta-adrenergic blocking drugs in ischemic heart disease: current concepts.

  1983cited by this paper
• Binding characteristics of 3H-dihydroalprenolol to beta-adrenoceptors of rat heart treated with neuraminidase.

  1983cited by this paper
• Adrenergic receptors in man: direct identification, physiologic regulation, and clinical alterations.

  1982cited by this paper
• Ventricular Antiarrhythmic Effects of Beta‐Adrenergic Blocking Drugs: A Review of Mechanism and Clinical Studies

  1982cited by this paper
• An investigation of the comparative liposolubilities of β‐adrenoceptor blocking agents

  1981cited by this paper
• The clinical importance of cardioselectivity and lipophilicity in beta blockers.

  1980cited by this paper
• Clinical pharmacology of the new beta-adrenergic blocking drugs. Part 3. Comparative clinical experience and new therapeutic applications.

  1979cited by this paper
• Clinical pharmacology of the new beta-adrenergic blocking drugs. Part 1. Pharmacodynamic and pharmacokinetic properties.

  1979cited by this paper
• Plasma concentrations of propranolol and 4-hydroxypropranolol in man measured by high pressure liquid chromatography.

  1979cited by this paper
• Isoproterenol antagonism of cardioselective beta adrenergic receptor blocking agents: a comparative study of human and guinea-pig cardiac and bronchial beta adrenergic receptors.

  1976cited by this paper
• Correlation of Plasma Propranolol Concentration with Therapeutic Response in Patients with Angina Pectoris

  1975cited by this paper
• Beta-adrenergic receptor blocking drugs in cardiac arrhythmias.

  1974cited by this paper
• Blocking of inhibitory adrenergic receptors by a dichloro analog of isoproterenol.

  1958cited by this paper
• Receptor Occupancy and Tissue Response

  1956cited by this paper
• Affinity and intrinsic activity in the theory of competitive inhibition. I. Problems and theory.

  1954cited by this paper
• The reaction between acetyl choline and muscle cells

  1926cited by this paper

• Carvedilol Improves Uptake-1 in Patients With Systolic Congestive Heart Failure

  2012cites this paper
• Pharmacokinetic Interactions of Antihypertensive Drugs with Citrus Juices

  2012cites this paper
• Quantitative structure-interaction relationship analysis of 1,4-dihydropyridine drugs in concomitant administration with grapefruit juice.

  2012cites this paper
• PHARMACOKINETIC / PHARMACODYNAMIC ( PK / PD ) MODELING : AN INVESTIGATIONAL TOOL FOR DRUG DEVELOPMENT

  2012cites this paper
• [Evaluation of the development of gastroduodenal lesions in patients treated with low-dose aspirin or non-steroidal anti-inflammatory drugs].

  2011cites this paper
• The effect of plasma protein binding on in vivo efficacy: misconceptions in drug discovery

  2010cites this paper
• Relationship between lipophilicities of 1,4-dihydropyridine derivatives and pharmacokinetic interaction strengths with grapefruit juice.

  2008cites this paper
• [Analysis of antiemetic effect of various dosage regimens of azasetron hydrochloride based on 5-HT3 receptor occupancy of serotonin].

  2007cites this paper
• Pharmacokinetics/pharmacodynamics analysis of the relationship between the in vivo micturition pressure and receptor occupancy of (R)-oxybutynin and its metabolite in rats.

  2007cites this paper
• Major determinant factors of the extent of interaction between grapefruit juice and calcium channel antagonists.

  2006cites this paper
• Receptor occupancy theory-based analysis of antiemetic effects and standard doses of 5-HT3 receptor antagonists in cancer patients

  2004cites this paper
• Influence of peripheral iridectomy on intravitreous penetration of topical nipradilol

  2004cites this paper
• [Pharmacokinetic/pharmacodynamic analysis of anti-hyperprolactinemic effect of terguride based on dopamine D2 receptor occupancy].

  2003cites this paper
• Betaxolol-induced deterioration of asthma and a pharmacodynamic analysis based on beta-receptor occupancy.

  2003cites this paper
• Nightmares and Panic Disorder Associated with Carvedilol Overdose

  2002cites this paper
• Rapid Determination of Partition Coefficients Between n-Octanol/Water for Cardiovascular Therapies

  2002cites this paper
• Prediction and assessment of extrapyramidal side effects induced by risperidone based on dopamine D2 receptor occupancy

  2002influential citation
• Clinical Application of Pharmacokinetics/Pharmacodynamics —From Animal to Human, and Normal to Disease

  2001cites this paper
• Lipophilicity in PK design: methyl, ethyl, futile

  2001cites this paper
• Assessment of Systemic Adverse Reactions Induced by Ophthalmic β-Adrenergic Receptor Antagonists

  2001cites this paper
• The use of preclinical pharmacokinetic and pharmacodynamic data to predict clinical doses: current and future perspectives

  2001cites this paper
• Quantitative structure-property relationships in pharmaceutical research - Part 2.

  2000cites this paper
• Quantitative Prediction of the Pharmacological Effects and Averse Reactions Based on Pharmacokinetics and Pharmacodynamics.

  2000cites this paper
• Pharmacokinetic-pharmacodynamic modeling: why?

  2000cites this paper
• Multivariate quantitative structure-pharmacokinetic relationships (QSPKR) analysis of adenosine A1 receptor agonists in rat.

  1999cites this paper
• Combined molecular lipophilicity descriptors and their role in understanding intramolecular effects.

  1999cites this paper
• [Kinetic analysis of therapeutic doses of beta-blockers for angina pectoris based on receptor occupancy theory--relationship between beta 1-receptor occupancy or vasodilative action and dose].

  1999cites this paper
• Contribution of P‐glycoprotein to bunitrolol efflux across blood–brain barrier

  1999cites this paper
• [Quantitative evaluation of pharmacological effects and adverse effects based on receptor occupancy theory].

  1997cites this paper
• Design of drugs involving the concepts and theories of drug metabolism and pharmacokinetics

  1996cites this paper
• Risk assessment of adverse pulmonary effects induced by adrenaline β-receptor antagonists and rational drug dosage regimen based on receptor occupancy

  1995cites this paper
• Prediction of sleep disorders induced by β-adrenergic receptor blocking agents based on receptor occupancy

  1995cites this paper